Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT
2025 ASCO Annual Meeting
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We enrolled 216 patients at 37 hospitals in six countries of Europe, and out of those, 170 patients were randomized to receive either one year of atezolizumab or observation. The main endpoint was overall survival, and unfortunately we did not see any signal of an effect, neither for progression-free survival, so this is clearly a negative trial. Looking at subgroups, we do see that there are some differences in the effect depending on gender. Among women, patients on the observation arm lived much longer than expected, while among men there appears to be a signal of an effect. We also see that the choice of platinum had some influence on the survival curves. We see that among patients who received carboplatin, maybe there's a signal of an effect quite similar to what we actually saw also in the ADRIATIC trial. Median treatment time was 8 courses. Overall, there were more side effects in the experimental arm, but maybe not any single adverse event—it's more the totality. On the other hand, patients on the observation arm didn't meet the investigators as often as the patients who came regularly for infusions of atezolizumab. I think overall this study shows that the concept of adding checkpoint inhibitors after chemoradiated therapy in limited-stage small cell lung cancer is tolerable, even if this intervention did not prolong PFS or overall survival.
The ASCO Post Staff
Frank A. Sinicrope, MD, of Mayo Clinic Rochester, reviews findings from the randomized Alliance A021502/ATOMIC trial, which studied standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III DNA mismatch repair–deficient (dMMR) colon cancer (LBA1).
The ASCO Post Staff
Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639).
The ASCO Post Staff
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004).
The ASCO Post Staff
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, Germany, discusses data from the phase III AEGEAN trial that studied perioperative durvalumab and neoadjuvant chemotherapy. Patients who were MRD-positive after surgery had significantly worse disease-free survival compared to MRD-negative patients. In addition, mutations in KEAP1 and KMT2C were associated with MRD positivity and reduced benefit from the regimen, identifying a small high-risk subgroup with poor prognosis (Abstract 8009).
The ASCO Post Staff
Sameek Roychowdhury, MD, PhD, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center, discusses a recently opened telemedicine clinical trial of pemigatinib in patients with advanced or metastatic FGFR-mutated pancreatic cancer, and the germination of a new initiative, TNT Cancer, which focuses on leveraging telemedicine to bring trials nationwide.
